<DOC>
	<DOCNO>NCT01744626</DOCNO>
	<brief_summary>This dose find study use 3 + 3 dose escalation expansion design determine Not Tolerated Dose ( NTD ) , Optimal Biological Effect Dose ( OBE ) / Maximum Tolerated Dose ( MTD ) . These data use establish Recommended Phase 2 Dose ( RP2D ) combination CC-292 Rituximab subject CLL .</brief_summary>
	<brief_title>Safety Study CC-292 Rituximab Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>This dose find study use 3 + 3 dose escalation expansion design establish recommend Phase 2 dose ( RP2D ) . Treatment consist 28 day treatment cycle single Rituximab infusion per cycle 6 cycle twice daily ( day 1-28 ) administration CC-292 start dose cohort 375mg twice day . Following safety review data initial cohort confirmation initial dose tolerable , next dose level enrol per cycle Rituximab infusion 6 cycle twice daily CC-292 500 mg . Determination maximum tolerate dose and/or optimal biologic effect use establish dose evaluation expansion cohort 24 subject . Evaluation data subject expansion cohort result establishment RP2D .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Male female subject 18 year age old time signing informed consent document . 2 . Understand voluntarily sign informed consent document ( ICD ) prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Body weight ≥ 50 kg . 5 . Must document diagnosis Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL/SLL ) ( International Workshop ) guideline diagnosis treatment CLL ( Appendix A ) , lymphoma guideline ( Appendix B ) diagnosis treatment SLL investigator assessment . 6 . Have fail ≥ 1 previous treatment CLL/SLL , relapse refractory disease follow last prior treatment . 1 . Refractory define CLL/SLL achieve least partial response ( PR ) therapy progress within 6 month treatment . Relapsed CLL/SLL refers disease progress ≥ 6 month subject achieve PR complete response ( CR ) therapy . 2 . Subjects must fail , refuse , ineligible , otherwise appropriate , per investigator 's judgment , autologous stem cell transplant ( SCT ) unless enrollment study anticipate debulk lesion preparation SCT . 7 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) ≤ 2 8 . Life expectancy least 3 month form time sign ICD . 9 . Females childbearing potential ( FCBP ) must negative medically supervised pregnancy test prior start study therapy . 10 . Male subject must : 1 . Agree use condom sexual contact FCBP , even vasectomy , throughout study drug treatment , dose interruption 28 day end study therapy . 2 . Agree donate semen study drug treatment 28 day end study drug treatment . 11 . Ability swallow oral capsule without difficulty . 12 . Have echocardiogram multigated acquisition scan heart demonstrate leave ventricular ejection fraction ( LVEF ) ≥ 50 % institution 's low limit normal . 13 . Have recover adverse , toxic effect prior therapy Grade ≤ 1 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI/CTCAE ) version 4.03 except alopecia peripheral neuropathy . This requirement subordinate specific clinical laboratory criterion otherwise specifically addressed inclusion/exclusion criterion . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Any condition confound ability interpret data study . 4 . Autologous stem cell transplant within 3 month screen date . 5 . Uncontrolled intercurrent illness include , limited : 1 . Ongoing active infection require parenteral antibiotic . 2 . Uncontrolled diabetes mellitus defined investigator . 3 . Chronic symptomatic congestive heart failure ( Class III IV New York Heart . Association Classification Heart Disease ; AppendixG ) . 4 . Unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month sign ICD . 5 . Clinically significant cardiac arrhythmia symptomatic require treatment , asymptomatic sustain ventricular tachycardia . Subjects control atrial fibrillation asymptomatic eligible . 6 . Pregnant lactating female . 7 . Prior history malignancy , unless subject free disease ≥ 3 year sign informed consent . Exceptions ≥ 3 year time limit include history following : 1 . Basal cell carcinoma skin . 2 . Squamous cell carcinoma skin . 3 . Carcinoma situ cervix . 4 . Carcinoma situ breast . 5 . Carcinoma situ bladder . 6 . Incidental histologic find prostate cancer ( TNM stage T1a T1b ) . ( The TNM stag system base extent tumor ( T ) , whether cancer cell spread nearby ( regional ) lymph node ( N ) , whether distant ( part body ) metastasis ( M ) occur ) . 8 . Known seropositivity history active viral infection Human Immunodeficiency Virus ( HIV ) . 9 . Seropositive active viral infection Hepatitis B virus ( HBV ) : 1 . HBV surface antigen positive . 2 . HBV surface antigen negative , HBV surface antibody positive and/or HBV core antibody positive detectable viral deoxyribonucleic acid ( DNA ) . Note : Subjects HBV surface antigen negative viral DNA negative eligible . 3 . Subjects HBV receive antiviral treatment show detectable viral DNA within 6 month sign ICD eligible . 4 . Subjects exhibit classical vaccination profile HBV surface antibody positive , HBV core antibody negative , HBV surface antigen negative eligible . 10 . Known seropositivity active viral infection Hepatitis C virus ( HCV ) . 11 . Subjects high risk thromboembolic event willing take venous thromboembolic event ( VTE ) prophylaxis . 12 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) ≤ 1,000 cells/mm3 ( 1.0 x 109/L ) unless secondary bone marrow involvement lymphoma demonstrate recent bone marrow aspiration bone marrow biopsy . 2 . Platelet count ≤ 50,000/mm3 ( 50 x 109/L ) unless secondary bone marrow involvement lymphoma demonstrate recent bone marrow aspiration bone marrow biopsy . Note growth factor transfusion administer screen sole purpose help subject exceed exclusionary laboratory value . 3 . Serum Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase ( AST/SGOT ) Alanine Transaminase/Serum Glutamic Pyruvate Transaminase ( ALT/SGPT ) &gt; 3.0 x Upper Limit Normal ( ULN ) &gt; 5.0 x ULN case document liver involvement lymphoma . 4 . Serum bilirubin &gt; 1.5 x ULN &gt; 3.0 x ULN case Gilbert 's Syndrome document liver involvement lymphoma . 5 . Calculated creatinine clearance use CockcroftGault formula ( Cockcroft , 1976 ) . For subject enrol Part 1 creatinine clearance value must &lt; 30 mL/min For subject enrol Part 2 creatinine clearance value must &lt; 60 mL/min 6 . Corrected QT interval ( QTc ) prolongation ( define QTc &gt; 450 msec male &gt; 470 msec female [ Fridericia 's correction ] echocardiogram ( ECGs ) clinically significant ECG abnormality assess investigator . An average 3 QTc interval may obtain necessary . 7 . Evidence Tumor Lysis Syndrome ( TLS ) per CairoBishop definition laboratory TLS ( [ Appendix F ] subject may enrol upon correction electrolyte abnormality ) . 13 . Prior exposure Bruton Tyrosine Kinase inhibitor . 14 . Chemotherapy , radiotherapy , investigational anti cancer therapy major surgery within 28 day Day 1 dosing . 15 . Use systemic corticosteroid dos great prednisone equivalent 20 mg/day within 3 week prior first dose study drug treatment . 16 . Concomitant use medicine know cause QT prolongation torsades de pointes ( Appendix I ) . 17 . Chronic use H2 antagonists proton pump inhibitor use within 7 day first dose study drug treatment . Subjects chronic gastroesophageal reflux disease , dyspepsia , peptic ulcer disease , carefully evaluate suitability treatment prior enrollment study . 18 . Gastrointestinal abnormality include ability take oral medication , require intravenous ( IV ) alimentation , prior surgical procedure affect absorption . 19 . History hypersensitivity reaction Rituximab . 20 . Any vaccination incorporate use live vaccine within 3 week first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
</DOC>